CN EN
CN EN

Science & Pipeline

A Robust Drug Discovery Platform Has Been Established
to Develop Novel, Potent and Safe RNAi Therapeutics

Pipeline

Target Organ
Indications
Targets
Candidate Screening
PCC Nomination
IND Enabling
IND
Early Development
Late Development
  • Hypercholesterolemia
    PCSK9
    Immunology-related disease
    Undisclosed
    Cardiovascular
    Undisclosed
    Others
    Undisclosed
  • CNS
    Undisclosed
    Others
    Undisclosed
Hepatic
Extrahepatic
TBD: To Be Disclosed
Terms of use | Privacy Policy

Copyright © 2023 Suzhou Sanegene Bio Inc. All rights reserved 

  • Home
  • Phone
  • Top